{"id":"NCT03417245","sponsor":"Genzyme, a Sanofi Company","briefTitle":"A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors","officialTitle":"ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-01","primaryCompletion":"2021-01-26","completion":"2021-07-14","firstPosted":"2018-01-31","resultsPosted":"2022-02-04","lastUpdate":"2022-03-28"},"enrollment":120,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A","Hemophilia B"],"interventions":[{"type":"DRUG","name":"fitusiran","otherNames":[]},{"type":"DRUG","name":"factor concentrates","otherNames":[]}],"arms":[{"label":"Factor On-demand","type":"EXPERIMENTAL"},{"label":"Fitusiran 80 mg Prophylaxis","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\n-To evaluate the efficacy of fitusiran compared to on-demand treatment with factor concentrates, as determined by the frequency of bleeding episodes.\n\nSecondary Objectives:\n\n* To evaluate the efficacy of fitusiran compared to on-demand treatment with factor concentrates, as determined by:\n\n  * The frequency of spontaneous bleeding episodes.\n  * The frequency of joint bleeding episodes.\n  * Health-related quality of life (HRQOL) in participants \\>=17 years of age.\n* To determine the frequency of bleeding episodes during the onset period.\n* To determine the safety and tolerability of fitusiran.","primaryOutcome":{"measure":"Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period","timeFrame":"From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest","effectByArm":[{"arm":"Factor On-demand","deltaMin":30.991,"sd":null},{"arm":"Fitusiran 80 mg Prophylaxis","deltaMin":3.133,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":64,"countries":["United States","Australia","China","Denmark","France","Germany","Hungary","India","Israel","Italy","Japan","Malaysia","South Africa","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["37003278","34922648"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":40},"commonTop":["Alanine Aminotransferase Increased","Nasopharyngitis","Upper Respiratory Tract Infection","Aspartate Aminotransferase Increased","Abdominal Pain"]}}